Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.

Authors

Valeria Santini, Rami S Komrokji, Michael R Savona, María Díez-Campelo, Pierre Fenaux, Mikkael A Sekeres, Yazan F Madanat, David Valcárcel, Anna Jonášová, Petra Belohlavkova, Tymara Berry, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Ying Wan, Fei Huang, Faye Feller, Shyamala Navada, Amer M Zeidan, Uwe Platzbecker

Published in

Haematologica. Sep 03, 2026. Epub Sep 03, 2026.

Abstract

Not available.

PMID:
42687814
Bibliographic data and abstract were imported from PubMed on 03 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.